LGVN
Longeveron Inc.
There isn't enough reported data to score LGVN yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
LGVN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
LGVN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
LGVN PE Valuation
LGVN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
LGVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect LGVN's losses to shrink, with revenue growing.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LGVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$62.80 | +$35.42 |
| Q2 2024 | -$87.40 | +$7.82 |
| Q1 2024 | -$96.10 | -$0.88 |
| Q4 2023 | -$102.00 | -$11.78 |
| Q3 2023 | -$98.22 | -$7.93 |
| Q2 2023 | -$95.22 | -$4.93 |
| Q1 2023 | -$95.22 | -$5.93 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 164% for LGVN versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
LGVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $115K | -16% |
| Q2 2026 | $287K | -9.2% |
| Q1 2026 | $398K | +4.5% |
| Q4 2025 | $365K | -39% |
| Q3 2025 | $137K | -82% |
| Q2 2025 | $316K | -32% |
| Q1 2025 | $381K | -30% |
| Q4 2024 | $603K | +857% |
LGVN's revenue has slid since its 2020 peak: $115,000 last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6258% | -923 points |
| Q2 2026 | -2150% | -442 points |
| Q1 2026 | -1200% | +160 points |
| Q4 2025 | -1479% | -769 points |
| Q3 2025 | -5336% | -4734 points |
| Q2 2025 | -1708% | -960 points |
| Q1 2025 | -1360% | -614 points |
| Q4 2024 | -710% | +7925 points |
LGVN's operating margin was −6258% last quarter, down 922 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over LGVN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over LGVN on profitability, with a higher operating margin.
LGVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | +$2.4M |
| Q2 2026 | -$5.8M | -$2M |
| Q1 2026 | -$4.4M | +$354K |
| Q4 2025 | -$5.3M | -$1.9M |
| Q3 2025 | -$5.1M | -$1.8M |
| Q2 2025 | -$3.8M | +$1M |
| Q1 2025 | -$4.7M | -$1.6M |
| Q4 2024 | -$3.4M | +$775K |
LGVN has burned cash in almost every quarter: −$18M over the past year, against −$17M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over LGVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
LGVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +159% | +400K shares |
| 1 year | +208% | +440K shares |
| 3 years | +243% | +461K shares |
LGVN has 650,988 diluted shares, up 208% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | $141,000 |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over LGVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
LGVN Net Leverage
LGVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
LGVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.1 | Neutral |
| Stochastic | 11.1 | Oversold |
LGVN's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
LGVN PE vs Healthcare Sector
LGVN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
LGVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.16 | 38% above |
| 20 week MA | $4.85 | 39% below |
| 50 week MA | $6.35 | 53% below |
| 100 week MA | $9.53 | 69% below |
| 200 week MA | $83.3 | 96% below |
LGVN has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 96% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over LGVN on trend strength, trading above more of its moving averages.
LGVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $741.0 | $1,370.0 | +85% |
| 2022 | $1,370.0 | $327.0 | -76% |
| 2023 | $327.0 | $136.0 | -58% |
| 2024 | $136.0 | $17.5 | -87% |
| 2025 | $17.5 | $5.32 | -70% |
| 2026 YTD | $5.32 | $2.97 | -44% |
LGVN has finished four years in a row lower, and it's down 44% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over LGVN on returns for 2026, with the stronger performance.